Vesicants toxicity

Role of Skin Mast Cells in Vesicant Toxicity.274... 

May discolor urine (red-orange) Liposomal form decreased risk of cardiac and vesicant toxicity... 

May discolor urine (red-orange) Dexrazoxane (Zinecard), a cardioprotectant, decreases risk of cardiotoxicity approved for use in breast cancer patients with >300 mg/m doxorubicin concerns over possible tumor protection limit its use Liposomal form decreased risk of cardiac and vesicant toxicities... 

Both chloramine-T and dichloramine-T have marked antiseptic properties, chloramine-T being most frequently used because of its solubility in water. Aqueous solutions of chloramine-T can be used either for external application, or for internal application to the mouth, throat, etc, as chloramine-T in moderate quantities is non-toxic its aqueous solution can also be effectively used when the skin has come in contact with many of the vesicant liquid poison-gases, as the latter are frequently organic sulphur or arsenic derivatives which combine with or are oxidised by chloramine-T and are thus rendered harmless. 

The procedure by which mustard is manufactured can be modified to yield either a mixture of mustard and Q (HQ) or a mixture of mustard and T (HT). These mixtures have several advantages over mustard alone, unless the agent is used only for vapor effects. HQ and HT are both more toxic, more vesicant, more persistent, and have lower melting points than mustard alone. 

It is used by direct instillation into the bladder for multifocal local bladder carcinoma. Nausea and myelosuppression are the major toxicities of thiotepa. It is not a local vesicant and has been safely injected intramuscularly and even intra-thecally. 

Myelosuppression (dose-related) mucositis (worse with continuous infusion) moderate emetogenic potential alopecia vesicant severe extravasation injury cardiac toxicities acute—not related to cumulative dose arrhythmias, pericarditis chronic— cumulative injury to myocardium (total dose greater than 550 mg/m2 lower total cumulative doses cause damage to myocardium in children (e.g., 350 mg/m2)... 

Peripheral neuropathy primary dose-limiting toxicity motor sensory, autonomic, and cranial nerves may all be affected (paresthesias, ileus, urinary retention, facial palsies) may be irreversible mild emetogen SIADH vesicant extravasation injury... 

L-l is a vesicant (blister agent) also, it acts as a systemic poison, causing pulmonary edema, diarrhea, restlessness, weakness, subnormal temperature, and low blood pressure. In order of severity and appearance of symptoms, it is a blister agent, a toxic lung irritant, absorbed in tissues, and a systemic poison. When inhaled in high concentrations, it may be fatal in as short a time as 10 min. L-1 is not detoxified by the body. Common routes of entry into the body include ocular, percutaneous, and inhalation. 

It hydrolyses in acidic medium to form HC1 and nonvolatile (solid) chlorovinylarsenious oxide, which is a less potent vesicant than Lewisite L-2. Hydrolysis in alkaline medium, as in decontamination with alcoholic caustic or carbonate solution, produces acetylene and trisodium arsenate (Na3AS04). Therefore, decontaminated solution would contain toxic arsenic. 

Sesquimustard has not been typically listed as a chemical warfare agent until it was listed in the CWC Schedule I. It is one of the most powerful vesicants currently known and is highly toxic by inhalation. 

HD is a vesicant (blister agent) and alkylating agent producing cytotoxic action on the hematopoietic (blood-forming) tissues which are especially sensitive. The rate of detoxification of HD in the body is very slow, and repeated exposures produce a cumulative effect. It causes blisters, irritates the eyes, and it is toxic when inhaled. HD has been determined to be a human carcinogen by the International Agency for Research on Cancer. 

Doxorubicin—monitor cumulative dose for cardiac toxicity (not to exceed 550 mg/M2 or 450 mg/M2 with prior chest radiotherapy) vesicant—avoid extravasation use 50% for bilirubin 1.5-3.0 use 25% for bilirubin > 3.0... 

Epirubicin-monitor cumulative dose for cardiac toxicity (not to exceed 1000 mg/M2) vesicant—avoid extravasation... 

---